HER2 fragmentation and breast cancer stratification.
HER2 is a tyrosine kinase receptor whose overexpression in breast cancers correlates with poor prognosis. A subset of HER2-positive tumors also expresses a series of HER2 fragments, collectively known as p95HER2. These fragments are emerging as a valuable biomarker for this subset of patients, who have a particularly poor prognosis.
Arribas
Joaquín
J
Vall d'Hebron Institute of Oncology, Barcelona, Spain. jarribas@vhio.net
Parra-Palau
Josep Lluís
JL
Pedersen
Kim
K
D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000235:genetics* / Q000378:metabolism*; D005260:Female; D006801:Humans; D010446:Peptide Fragments / Q000032:analysis*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000378:metabolism*
D014408:Biomarkers, Tumor; D010446:Peptide Fragments; D018719:Erb-b2 Receptor Tyrosine Kinases